A woman from Texas, US, was promoting her home jewellery business live on TikTok when she suddenly began feeling disoriented and fainted. According to 43-year-old Kristie Kaluza, she felt as if she fainted but tried to remain awake and upright. Later, it was found that she was suffering from a stroke.

Here's What Exactly Happened

Kristie Kaluza, 43, from El Campo, Texas, was recording a video to showcase her jewellery when she suddenly felt something was off. "I didn't fall. I wasn't on the floor, but I realised I had dropped the jewelry, and my brain was really confused," Kaluza said. "I looked up at the camera because I knew my husband was (watching), and I tried to say, 'I need help,' and it wouldn't come out. I couldn't turn my body. I felt super heavy. I couldn't really lift my arms."

Her husband, who was watching her live on camera, immediately sensed something was wrong and called emergency services. At the hospital, however, Kristie’s symptoms were initially dismissed. "The people at the hospital ... said, 'You're so young," she recalls. "I come to find out when we finally get to the neurologist … it was a stroke."

Unexpected Sensation

Kristie said she had just sat down to film a new video for her jewellery collection when the strange sensation hit her, and she realised she couldn’t speak. “There’s a miscommunication, a misfire there somewhere, and I couldn’t get out that, ‘Hey, I don’t feel good,’” she says.

As her husband rushed to get help, Kristie began experiencing tremors in her head and hands. “That was one of the scariest things, not being able to say my words and not having control of my head or my hands,” she says.

She did manage to reach the hospital, and an MRI confirmed the diagnosis. Later, doctors administered a blood-thinning medication, which breaks up a blood clot. She was released and underwent an outpatient MRI.

A recent study published in The New England Journal of Medicine has revealed that mass administration of ivermectin, a drug long used for treating river blindness and scabies, can significantly reduce malaria transmission when combined with insecticide-treated bed nets.

The findings come from the BOHEMIA trial, the largest study of its kind, which demonstrated a 26% reduction in new malaria infections on top of existing prevention methods.

What Does The Study Say: The BOHEMIA Trial

The BOHEMIA project (Broad One Health Endectocide-based Malaria Intervention in Africa) was coordinated by the Barcelona Institute for Global Health (ISGlobal), with support from the “la Caixa” Foundation, and conducted in collaboration with the Manhica Health Research Centre (CISM) in Mozambique and the KEMRI-Wellcome Trust Research Programme in Kenya.

The trial involved two large-scale Mass Drug Administration (MDA) programs in Kwale County, Kenya, and Mopeia district, Mozambique. Participants received a monthly dose of ivermectin (400 mcg/kg) for three consecutive months during the rainy season. In total, more than 20,000 participants took part, and over 56,000 treatments were administered.

Why Is A New Approach Needed?

Malaria remains a major global health threat. In 2023 alone, there were 263 million cases worldwide, leading to nearly 600,000 deaths. Standard prevention measures such as long-lasting insecticidal nets (LLINs) and indoor residual spraying (IRS) have been losing effectiveness due to growing insecticide resistance and changes in mosquito behavior. Mosquitoes increasingly bite outdoors or during hours when people are not under bed nets, limiting the reach of existing strategies.

Also Read: Fact Check: Can Ivermectin Really Treat Cancer?

This urgent challenge has fueled research into innovative tools like ivermectin. While the drug has historically been used against neglected tropical diseases such as onchocerciasis (river blindness) and lymphatic filariasis (elephantiasis), researchers have discovered that mosquitoes feeding on individuals treated with ivermectin die, thereby reducing malaria transmission.

Results From Kenya and Mozambique

In Kwale County, Kenya, where the intervention targeted children aged 5 to 15, ivermectin led to a 26% reduction in malaria incidence compared to the control group treated with albendazole. In Mozambique, where the study focused on children under five, the drug also showed promise in curbing transmission.

Importantly, the safety profile of ivermectin was reassuring. No severe adverse drug reactions were recorded, and only mild, short-lived side effects were reported, consistent with previous campaigns where the drug was used against other parasitic diseases.

Expert Reactions and Global Significance

Researchers leading the trial have expressed optimism. “Ivermectin has shown great promise in reducing malaria transmission and could complement existing control measures. With continued research, it could become an effective tool for malaria elimination,” said Carlos Chaccour, co-principal investigator of the BOHEMIA project.

The findings also meet the World Health Organisation’s (WHO) criteria for evaluating new vector control tools. According to Joseph Mwangangi of the KEMRI-Wellcome Trust Research Programme, ivermectin could be a vital complementary strategy in areas grappling with insecticide resistance. BOHEMIA’s lead entomologist, Marta Maia of the University of Oxford, echoed this view, noting that the results highlight ivermectin’s potential to bolster malaria control programs.

What Comes Next?

The WHO vector control advisory group has reviewed the findings and confirmed their impact, recommending further large-scale studies. Results have also been shared with national health authorities, who will consider whether ivermectin should be included in official malaria control programs.

While more evidence is needed, the BOHEMIA trial marks a significant step forward in the global fight against malaria. If scaled effectively, ivermectin could become a powerful complement to existing tools, offering new hope in reducing the burden of one of the world’s deadliest diseases.

A new global analysis published in The Lancet has revealed that the probability of dying from non-communicable diseases (NCDs) such as cancer, diabetes, and heart disease has increased in India over the past decade. The study points out that while four out of every five countries saw a decline in chances of dying from a chronic disease, India may stand as an outlier in this health trend.

The study, conducted by researchers from Imperial College London, the World Health Organisation (WHO), and other global institutions, looked at mortality data from 185 countries and territories between 2010 and 2019. India registered a worrying rise, with women experiencing a sharper increase than men.

Also Read: A Viral Instagram Post Makes Several Claims On What Makes Your Kids Sick After A Swimming Session, We Fact Checked It For You, Here's What We Found

What the Numbers Show

Globally, the probability of dying from an NCD between birth and age 80 declined in 82% of countries for females and in 79% for males. These improvements were largely due to fewer deaths from cardiovascular diseases, certain cancers, and conditions such as stroke.

In stark contrast, India joined a small group of countries, including Papua New Guinea,, where deaths from chronic illnesses went up for both genders. The analysis noted that “deaths from most causes of chronic disease increased in India, with heart disease and diabetes contributing heavily.”

The report also underlined that among large nations, countries such as China, Egypt, Nigeria, Russia, and Brazil recorded declines in both male and female chronic disease death risks, highlighting India’s outlier status.

Women Face Higher Risk

The Lancet study highlighted an alarming gender divide in India. While both men and women saw an increase in mortality risk, the rise was steeper for women. This suggests that Indian women are facing growing vulnerability to lifestyle-related illnesses such as diabetes and cardiovascular conditions, potentially compounded by limited access to timely diagnosis and treatment.

Also Read: A Higher Dose Of Semaglutide Helps 1 In 3 Obese Adults Lose 25% Body Weight: Lancet Study

Globally, women have generally benefited more from improved chronic disease management compared to men. India’s reversal of that trend raises fresh concerns about the country’s ability to meet health equity goals.

What Is Driving the Trend?

Experts say India’s growing urbanization, dietary changes, sedentary lifestyles, and high levels of air pollution are fueling the surge in NCDs, as is also stated in a recent 2025 study published in Cureus, titled: Urban-Rural Health Transitions in India: A Comprehensive Review of Non-communicable Disease Trends and Risk Landscapes. Additionally, another 2023 study published in Cureus, titled: The Transformation of The Indian Healthcare System, notes that the country has long struggled with health system constraints, including unequal access to preventive and primary care.

While deaths from communicable diseases have declined due to better vaccination and treatment, the vacuum has been filled by chronic conditions that demand long-term management. The study points to heart disease and diabetes as the leading drivers of India’s rising death risk, alongside growing cases of dementia, alcohol-related disorders, and cancers of the pancreas and liver.

Global Commitments Under Pressure

The findings come at a critical time. Nations, under the United Nations’ Sustainable Development Goals (SDGs), have pledged to reduce premature mortality from NCDs by one-third by 2030. The upcoming Fourth High-Level Meeting of the UN General Assembly is expected to set out a new vision for tackling these conditions, including scaling up prevention and treatment.

For India, however, the new data suggests the country risks falling further behind on these global commitments.

The past year we have observed more and more incorporation of AI in different aspects of our life. Not just for writing or making pictures, it is also now being used to identify people’s faces through facial recognition software, helping in documentation as well as in medicine. New software are being developed to assist medical professionals, not only does this help them identify diseases but also speeds up the process.

Having AI in medicine could also lower the cost and help many people get the help they need. This has led researchers to look for different ways to teach AI how to recognize and diagnose issues. One such disease that can cause people blindness, could actually be identified by AI, according to new research.

A new study has shown that artificial intelligence (AI) can accurately predict which patients with a condition called keratoconus need treatment to save their vision. This research, presented at the 43rd Congress of the European Society of Cataract and Refractive Surgeons (ESCRS), is a major breakthrough for managing this eye disease, which often affects young adults. The findings were shared at a major conference for eye surgeons.

What is Keratoconus?

Keratoconus is an eye condition where the cornea, the clear, front part of the eye, starts to bulge outwards and change shape. This causes vision to become blurry and distorted. If the condition gets worse, a person might eventually need a cornea transplant, which is a major surgery.

Right now, doctors can only track the disease by having patients come in for frequent check-ups over many years. This is time-consuming for both the patient and the hospital. The main treatment, called cross-linking, is very successful at stopping the disease, but doctors haven't had a reliable way to know which patients will get worse and need the treatment right away versus those who can just be watched.

How the AI Algorithm Works For Medicine

Researchers from a London eye hospital and a university created an AI program to help with this problem. They trained the AI using over 36,000 images of patients' eyes taken with a special scanner. The AI looked at these images and other patient data to learn how to predict the disease's future course.

The AI's performance was very impressive. It was able to correctly sort patients into two groups from their very first visit: a low-risk group that didn't need immediate treatment, and a high-risk group that did. The AI was correct about two-thirds of the time. When the researchers added data from a second visit, the AI's accuracy jumped to 90%, meaning it was right nine out of ten times.

Patient Care

This new AI tool could change how doctors treat keratoconus. By using the AI to identify high-risk patients early, doctors could perform the preventative cross-linking treatment before vision gets worse. This would help patients avoid vision loss and the need for a major surgery like a corneal transplant.

For low-risk patients, the AI would prevent them from having to make unnecessary and frequent hospital visits, which would also free up doctors and hospital resources. The researchers are now working on making the AI even better, with the goal of using it to help with other eye problems as well, such as infections and inherited diseases.